{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T10:48:31Z","timestamp":1792234111519,"version":"4.4.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,9,3]],"date-time":"2010-09-03T00:00:00Z","timestamp":1283472000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1007\/s11060-010-0371-x","type":"journal-article","created":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T22:30:38Z","timestamp":1283380238000},"page":"147-153","source":"Crossref","is-referenced-by-count":10,"title":["Feasibility study of 21-day-on\/7-day-off temozolomide in children with brain tumors"],"prefix":"10.1007","volume":"103","author":[{"given":"Vita","family":"Ridola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Barone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Lazzareschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ruggiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Riccardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,9,3]]},"reference":[{"key":"371_CR1","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/bjc.1992.57","volume":"65","author":"ES Newlands","year":"1992","unstructured":"Newlands ES, Blackledge GR, Slack JA, Rustin GJ, Smith DB, Stuart NS (1992) Phase I trial of temozolomide. Br J Cancer 65:287\u2013291","journal-title":"Br J Cancer"},{"key":"371_CR2","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1200\/JCO.1999.17.9.2762","volume":"17","author":"WK Yung","year":"1999","unstructured":"Yung WK, Prados MD, Yaya-Tur R et al (1999) Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse: Temodal Brain Tumor Group. J Clin Oncol 17:2762\u20132771","journal-title":"J Clin Oncol"},{"key":"371_CR3","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1200\/JCO.2002.08.141","volume":"20","author":"LS Lashford","year":"2002","unstructured":"Lashford LS, Thiesse P, Jouvet A et al (2002) Temozolomide in malignant gliomas of childhood: a United Kingdom children\u2019s cancer study group and French society for pediatric oncology intergroup study. J Clin Oncol 20:4684\u20134691","journal-title":"J Clin Oncol"},{"key":"371_CR4","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/sj.bjc.6601997","volume":"91","author":"AC Verschuur","year":"2004","unstructured":"Verschuur AC, Grill J, Vassal G et al (2004) Temozolomide in pediatric high-grade glioma: a key for combination therapy ? Br J Cancer 91:425\u2013429","journal-title":"Br J Cancer"},{"key":"371_CR5","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/00043426-200305000-00005","volume":"25","author":"DJ Kuo","year":"2003","unstructured":"Kuo DJ, Weiner HL, Wisoff J, Miller DC, Knopp EA, Finlay JL (2003) Temozolomide is active in childhood, progressive unresectable, low-grade gliomas. J Pediatr Hematol Oncol 25:372\u2013378","journal-title":"J Pediatr Hematol Oncol"},{"key":"371_CR6","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/pbc.21270","volume":"49","author":"SL Khaw","year":"2007","unstructured":"Khaw SL, Coleman LT, Downie PA, Heath JA, Ashley DM (2007) Temozolomide in pediatric low-grade glioma. Pediatr Blood Cancer 49:808\u2013811","journal-title":"Pediatr Blood Cancer"},{"key":"371_CR7","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1002\/cncr.22961","volume":"110","author":"HS Nicholson","year":"2007","unstructured":"Nicholson HS, Kretschmar CS, Krailo M et al (2007) Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children\u2019s Oncology Group. Cancer 110:1542\u20131550","journal-title":"Cancer"},{"key":"371_CR8","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1215\/15228517-2008-078","volume":"11","author":"W Wick","year":"2009","unstructured":"Wick W, Platten M, Weller M (2009) New (alternative) temozolomide regimens for the treatment of glioma. Neuro-Oncology 11:69\u201379","journal-title":"Neuro-Oncology"},{"key":"371_CR9","first-page":"1117","volume":"16","author":"DS Kong","year":"2006","unstructured":"Kong DS, Lee JI, Kim WS et al (2006) A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma. Oncol Rep 16:1117\u20131121","journal-title":"Oncol Rep"},{"key":"371_CR10","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1158\/1078-0432.CCR-08-0888","volume":"15","author":"S Kesari","year":"2009","unstructured":"Kesari S, Schiff D, Drappatz J et al (2009) Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clin Cancer Res 15:330\u2013337","journal-title":"Clin Cancer Res"},{"key":"371_CR11","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/sj.bjc.6600827","volume":"88","author":"AW Tolcher","year":"2003","unstructured":"Tolcher AW, Gerson SL, Denis L et al (2003) Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 88:1004\u20131011","journal-title":"Br J Cancer"},{"key":"371_CR12","first-page":"4342","volume":"63","author":"F Bertolini","year":"2003","unstructured":"Bertolini F, Paul S, Mancuso P et al (2003) Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 63:4342\u20134346","journal-title":"Cancer Res"},{"key":"371_CR13","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1200\/JCO.2001.19.4.1195","volume":"19","author":"KD Miller","year":"2001","unstructured":"Miller KD, Sweeney CJ, Sledge GW Jr (2001) Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 19:1195\u20131206","journal-title":"J Clin Oncol"},{"key":"371_CR14","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1124\/jpet.106.118265","volume":"321","author":"Q Zhou","year":"2007","unstructured":"Zhou Q, Guo P, Wang X, Nuthalapati S, Gallo JM (2007) Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimens. J Pharmacol Exp Ther 321:265\u2013275","journal-title":"J Pharmacol Exp Ther"},{"key":"371_CR15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11060-009-9891-7","volume":"95","author":"JJ Virrey","year":"2009","unstructured":"Virrey JJ, Golden EB, Sivakumar W et al (2009) Glioma-associated endothelial cells are chemoresistant to temozolomide. J Neurooncol 95:13\u201322","journal-title":"J Neurooncol"},{"key":"371_CR16","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987\u2013996","journal-title":"N Engl J Med"},{"key":"371_CR17","unstructured":"http:\/\/ctep.cancer.gov\/forms\/CTCAE.pdf . Accessed January 1, 2004"},{"key":"371_CR18","first-page":"117","volume":"49","author":"J Sterba","year":"2002","unstructured":"Sterba J, Pavelka Z, Slampa P (2002) Concomitant radiotherapy and metronomic temozolomide in pediatric high-risk brain tumors. Neoplasma 49:117\u2013120","journal-title":"Neoplasma"},{"key":"371_CR19","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1200\/JCO.2004.07.060","volume":"22","author":"YB Su","year":"2004","unstructured":"Su YB, Sohn S, Krown SE et al (2004) Selective CD4+\u00a0lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol 22:610\u2013616","journal-title":"J Clin Oncol"},{"key":"371_CR20","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11060-005-9011-2","volume":"77","author":"A Ruggiero","year":"2006","unstructured":"Ruggiero A, Cefalo G, Garr\u00e9 ML et al (2006) Phase II trial of temozolomide in children with recurrent high-grade glioma. J Neurooncol 77:89\u201394","journal-title":"J Neurooncol"},{"key":"371_CR21","first-page":"4363","volume":"58","author":"CS Brock","year":"1998","unstructured":"Brock CS, Newlands ES, Wedge SR et al (1998) Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res 58:4363\u20134367","journal-title":"Cancer Res"},{"key":"371_CR22","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1215\/15228517-4-1-39","volume":"4","author":"RB Khan","year":"2002","unstructured":"Khan RB, Raizer JJ, Malkin MG et al (2002) A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. Neuro-Oncology 4:39\u201343","journal-title":"Neuro-Oncology"},{"key":"371_CR23","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1200\/JCO.20.5.1375","volume":"20","author":"R Stupp","year":"2002","unstructured":"Stupp R, Dietrich P, Ostermann Kraljevic S et al (2002) Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20:1375\u20131382","journal-title":"J Clin Oncol"},{"key":"371_CR24","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/ncponc0514","volume":"3","author":"V Gani\u00e8re","year":"2006","unstructured":"Gani\u00e8re V, Christen G, Bally F et al (2006) Listeria brain abscess, Pneumocystis pneumonia and Kaposi\u2019s sarcoma after temozolomide. Nat Clin Pract Oncol 3:339\u2013343","journal-title":"Nat Clin Pract Oncol"},{"key":"371_CR25","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1016\/j.ejca.2006.03.023","volume":"42","author":"S Baruchel","year":"2006","unstructured":"Baruchel S, Diezi M, Hargrave D et al (2006) Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours. Eur J Cancer 42:2335\u20132342","journal-title":"Eur J Cancer"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-010-0371-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-010-0371-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-010-0371-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,3]],"date-time":"2019-06-03T04:15:58Z","timestamp":1559535358000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-010-0371-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,3]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["371"],"URL":"https:\/\/doi.org\/10.1007\/s11060-010-0371-x","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,3]]}}}